文献速递脑血管病

AFFINITY试验12个月结局:氟西汀对急性卒中后功能恢复的影响

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
PubMed 文献 · Stroke · 2021-05-21

AFFINITY试验在1280例急性卒中患者中比较口服氟西汀20mg/日与安慰剂治疗6个月的效果,12个月随访显示改良Rankin量表分布无差异(aOR 0.93,95%CI 0.76-1.14,P=0.46),跌倒、骨折、癫痫发作无显著增加,复发缺血性卒中减少(2.18% vs 4.55%,P=0.02)可能为偶然发现。

要点

  • 急性卒中后氟西汀20mg/日治疗6个月,12个月时功能结局无延迟或持续获益。
  • 12个月时跌倒、骨折、癫痫发作风险无显著增加。
  • 复发缺血性卒中减少可能为偶然发现,不应作为用药指征。

核心结论

  • 急性卒中后氟西汀20mg/日治疗6个月对12个月功能结局、跌倒、骨折或癫痫发作无延迟或持续影响。
  • 氟西汀组复发缺血性卒中率较低(2.18% vs 4.55%,P=0.02),最可能为偶然发现。

研究设计与样本

  • AFFINITY为随机、平行组、双盲、安慰剂对照试验,纳入1280例成人卒中患者。
  • 患者于卒中后2-15天随机分配至口服氟西汀20mg每日一次(n=642)或安慰剂(n=638)治疗6个月,随访至随机化后12个月。
  • 研究在澳大利亚29个、新西兰4个、越南10个共43个医院卒中单元开展,2013-2019年招募。

主要发现

  • 12个月时改良Rankin量表分类分布两组相似(调整共同OR 0.93,95%CI 0.76-1.14,P=0.46)。
  • 12个月时氟西汀组复发缺血性卒中有14例(2.18%),安慰剂组29例(4.55%),P=0.02。
  • 12个月时跌倒:氟西汀组27例(4.21%),安慰剂组15例(2.35%),P=0.08。
  • 12个月时骨折:氟西汀组23例(3.58%),安慰剂组11例(1.72%),P=0.05。
  • 12个月时癫痫发作:氟西汀组11例(1.71%),安慰剂组8例(1.25%),P=0.64。

关键数值与推荐

  • 主要结局为6个月时改良Rankin量表评估的功能状态。
  • 12个月次要结局包括改良Rankin量表、情绪、认知、整体健康状况、疲劳、健康相关生活质量及安全性。
  • 平均用药依从时间为167天(SD 48),两组相似。

临床怎么用

  • 不推荐急性卒中后常规使用氟西汀20mg/日以改善功能结局。
  • 若临床考虑使用氟西汀,应知晓12个月时跌倒、骨折、癫痫发作风险无显著增加。

局限性

  • 复发缺血性卒中减少可能为偶然发现,需谨慎解读。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. METHODS: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. RESULTS: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76-1.14]; P=0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P=0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P=0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P=0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P=0.64) at 12 months. CONCLUSIONS: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. Registration: URL: http://www.anzctr.org.au/; Unique identifier: ACTRN12611000774921.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Hankey GJ, Hackett ML, Almeida OP, et al. Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. Stroke. 2021. PMID: 34015940. doi:10.1161/STROKEAHA.120.033070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。